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CANCER HAS become an increasingly
important disease in canine populations,
partly as a result ofadvances in veterinary
medicine, where elimination of many
infectious diseases by vaccination has
considerably extended the average life-
span of dogs. Deaths are now more
frequentlyattributedtodiseasesofold age,
of which cancer is an imporant example
(Hannant et al., 1978).
Many diseases of dogs present a similar
clinico-pathological picture to their
counterparts in humans, and there are
several comparative studies relating clini-
cal and morphological aspects of canine
tumours. There are, however, few reports
existing on the adaptability of classic
markers of disease. A study of the
comparative pathology between human
and canine osteosarcoma (Owen, 1969)
showed that the biological behaviours of
this tumour is similar in the two species.
Other neoplasms of comparative medical
and veterinary interest include spontan-
eous mammary carcinoma (Owen, 1979)
where circulating immune complexes have
been demonstrated.
Immune complexes have been studied in
relation to the pathogenesis of human and
animal disorders including malignant dis-
eases (Hoffken et al., 1978b; Baldwin et al.,
1979; Terman et al., 1980). In recent years
sensitive techniques have been applied to
detect immune complexes in sera from
patients with many types of tumour
(reviewed by Baldwin & Robins, 1980).
Circulating immune complexes in human
osteosarcoma have been studied using the
Clq binding test by Tsang et al. (1979) and
in this laboratory by Segal-Eiras et al.
(1980).
The possibility of investigating a large
population of dogs with o.s. allowed the
development of the present study, in
which the incidence ofsera with raised Clq
binding could be determined, and a
preliminary investigation ofchanges in Clq
binding with disease progress could be
made.
These investigations were performed in
parallel with human bone-tumour
immune-complex studies, and used human
Clq, which has previously been shown to
bind rat (Hoffken et al., 1978a) and dog
(Terman et al., 1979) immune complexes.
Following the method of Yonemasu &
Stroud (1971) Clq was prepared and
purified from pooled normal human sera
and its purity was checked by
immunoelectrophoretic analysis. The Clq
preparation was radioiodinated with
lactoperoxidase (Heusser et al., 1973) to
give a sp. act. of lutCi/,ug. All studies
were performed with 1251 labelled Clq
stored no longer than 15 days at - 70°C.
Immune complexes were measured by 1251-
Clq binding test, following the method of
Zubler et al. (1976) essentially as pre-
viously described (Segal-Eiras et al., 1980).
The baseline serum Clq-binding levels
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TABLE I.-Serum 125I-Clg binding levels in dogs with osteosarcoma,
other tumours and healthy controls
Serum samples
Dog osteosarcoma
Other tumours
Non-malignant diseases
Healthy control
Clg binding*
(mean +s.d.)
39 9+ 14-7
34-4+ 14-2
11*2+ 3-0
8-5+2-7
Range
13- 1-64*4
21*9-64-3
7-5-14-8
5-5-12 *3
Number +vet
46/56
10/10
1/8
0/34
82-1
100
13 0
0
* 4-5 tests for each serum sample.
t >Mean+ 2 s.d. ofhealthy dogs group (14% Clg binding).
TABLE II.-Protein A affinity of Clq binding in serum ofdogs with osteosarcoma
% Clq binding (mean + s.e.)
Sera
Osteosarcoma 1
Osteosarcoma 2
Osteosarcoma (pool)
Normal dog (pool 1)
Before Protein A
Test separation unbound
1 19-9+0-2 5-2+0-1
2 28-8+0-5 4-5+0-2
1 18-3+1-1 5-6+0-1
1 26-1+1*9 3 0+0 5
2 31-5+2-0 2-5+0-4
1 6-2+0-5 24-9+0-7
2 4-7+0-6 18-8+ 1-5
Bound and
eluted
26-5+ 1-5
32 - 2 + 2 -9
19-7+0-5
25-8+0-2
29-2+ 0-4
5.0+ 0 1
2-6+0-1
Normal dog (pool 2) 1 9-1+ 0-3 23 - 5 + 0 - 3 5 3 + 0 3
Serum samples were applied to Sepharose 4B-CL Protein A columns. Unbound protein eluted in PBS
and bound fractions eluted with pH 2-8 buffer were neutralized, concentrated to the volume of the original
serum sample, dialysed against PBS and tested in the 125I-Clq binding assay.
for normal dogs was established in tests of
samples from 22 clinically healthy female
beagles aged 2-7 years, and 12 healthy
wolfhounds of both sexes with an age
range of 5-7 years. Clq-binding values
shown in Table I ranged from 5.5 to 12.3%
(mean 855 + 2.7%). For comparative pur-
poses, a high value was taken to be
>14.0% or mean+2 s.d. of the control
serum samples. Fifty-six dogs with spon-
taneous osteosarcoma confirmed at biopsy
or post mortem examination were studied;
most were of large breed (Owen, 1969).
Forty-six out of 56 serum samples from
dogs with osteosarcoma had high Clq-
binding levels ranging from 14 2 to 54-4
(mean 39.9+14.7%)/
Sera from dogs with either lympho-
sarcoma, fibrosarcoma or mammary car-
cinoma also had high levels in 10/10 cases;
range 21-9-64*3 (mean 34.4 + 13-4). In
contrast, sera from a small group of dogs
with non-malignant diseases, including
healing fractures, osteoarthritis, diabetes
melitus, otitis externa and skin diseases,
had low levels of Clq binding (1/8 positive,
range 7-5-14-8, mean 112 + 30).
Experiments were performed to investi-
gate the nature of the serum Clq binding
material by determining its affinity for
Protein A. Serum samples were dialysed
against buffered saline (PBS pH 7.2) and
applied to a 2ml column of Protein A-
Sepharose CL4B (Pharmacia) equilibrated
with the same buffer. Unbound material
was eluted with PBS, and bound fractions
eluted with 01M glycine HCl buffer
(pH 2.8). After neutralization, serum frac-
tions were concentrated to the original
volume, dialysed against PBS and centri-
fuged (800 g) for 30 min before testing in
the Clq-binding assay. Because of the
limited quantities of sera available, these
studies were performed using not only
individual samples but also from a pool of
sera from 3 dogs with o.s. (Table II). With
o.s. samples, the fractions which bound to
and eluted from Protein A immobilized on
Sepharose CL-4B gave Clq binding, com-
parable with that in the unfractionated
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FIG. 1. Sequential study of serum Clq bind-
ing levels in 4 dogs with osteosarcoma
without recurrence after one year. Dog C
was amputated and treated with BCG.
Dogs F, H and K received radiotherapy
(10 Gy from a linear accelerator to the
affected bone at weekly intervals, to a total
dose of 40 Gy).
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FIG. 2.- Sequential study of serum Clq bind-
ing levels in 8 dogs with osteosarcoma with
local recurrence and/or metastasis. Dogs A
and B were amputated and irradiated. Dogs
D, E, G, I and L received radiotherapy.
Dog J was amputated at diagnosis followe(d
by BCG and chemotherapy.
sample. Clq binding of the Protein A-
unbound material was normal, both in the
individual dogs with o.s. and the pooled
o.s. serum samples. The Protein A bound
and eluted fractions from two pools of
normal dog sera showed low Clq binding,
though the Protein A-unbound fractions of
these sera showed anomalous high Clq
binding. The basis of Clq binding from
these normal sera during fractionation is
not known.
Sequential serum samples were avail-
able from 12 dogs in this study. The results
of Clq-binding assays on sera from 4 dogs
surviving up to 1 year without recurrences
are shown in Fig. 1. This group of animals
had high Clq-binding levels before treat-
ment, which returned to the normal range
by 1 year. A further 8 dogs were studied
(Fig. 2) in which treatment was unsuccess-
ful. In these cases, Clq binding was high at
diagnosis, and remained high throughout
the disease course, or fell only transiently.
The demonstration of high Clq binding in
the serum of dogs with osteosarcoma, and
its relationship to the course of disease,
show similarities to earlier studies in
human osteosarcoma (Segal-Eiras et al.,
1980). One value of these sequential
studies lies in the fact that the canine
osteosarcoma has a more rapid course than
in man, and results on the effect oftherapy
and monitoring of the disease can be
obtained sooner.
Studies on the Protein A-Sepharose
affinity of osteosarcoma and normal dog
sera showed that in osteosarcoma sera, the
Clq binding appeared in the bound and low
pH-eluted fraction. On the contrary, the
values of Clq binding of the same fraction
from normal dogs were low. These results
suggest that the immune complexes detec-
ted with this test have components with
IgG characteristics, though the anomalous
Clq binding in the unbound fraction of
normal dog sera means that these results
must be regarded with caution.
The investigations show the adapt-
ability of a human clinical method to a
canine system and further studies will be
necessary to resolve the nature of these
immune complexes in canine osteosar-
coma.
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